RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Canopy Growth (NYSE:CGC) to transfer its U.S. stock exchange listing from NYSE to Nasdaq effective November 13, 2020 after market close.
The common shares are expected to begin trading on Nasdaq on November 16, 2020, with the shares continuing to trade under the symbol “CGC”.
NAI is hosting the GCFF Virtual Conference – Diversified Investing Strategies. Featuring over 12 public and private companies representing the newest innovations in healthcare, technology and investment, the event will provide our readers with the most exciting growth opportunities in 2020. Learn more at: https://nai500.com/events/gcff-2020-diversified-invest/.
Brazil’s health regulator Anvisa has signed off on the resumption of a clinical trial evaluating Johnson & Johnson’s (JNJ +0.2%) COVID-19 vaccine in adult volunteers. The study was paused in October pending the investigation into an unexplained illness of a participant, later deemed unrelated to the vaccine.
When the trial was halted, only 12 subjects had received either the vaccine or placebo. Up to 7,560 Brazilians could be enrolled.
J&J’s candidate is one of four being testing in Brazil, home of the world’s third largest outbreak after the U.S. and and India.
The U.S. portion of the 60K-subject study has also restarted.
Bausch Health Companies (NYSE:BHC): Q3 Non-GAAP EPS of $1.31 beats by $0.27; GAAP EPS of $0.20 beats by $0.47.
Revenue of $2.14B (-3.2% Y/Y) beats by $90M.
Non-GAAP EBITDA of $948M vs. consensus of $847.1M.
Shares +1.04% PM.
Avanos Medical (NYSE:AVNS): Q3 Non-GAAP EPS of $0.21 beats by $0.11; GAAP EPS of $0.40 beats by $0.44.
Revenue of $185.7M (+8.3% Y/Y) beats by $19.83M.
MiMedx (OTCPK:MDXG) to commence trading on Nasdaq on November 4, 2020, under the ticker symbol “MDXG”.